Table 1.
Demographic Details of Subjects Used for Analysis
| Total | Discovery | Validation | P value | ||||
|---|---|---|---|---|---|---|---|
| Schiz | Control | Group 1 | Group 2 | Group 1 | Group 2 | ||
| Number | 180 | 398 | 28 | 62 | 28 | 62 | — |
| Males/Females | 118/62 | 232/166 | 19/9 | 40/22 | 21/7 | 38/24 | .816 |
| Age (y) | 30±10 | 33±10 | 30±10 | 30±11 | 28±9 | 31±10 | .645 |
| Body mass index (kg/m2) | 24±5 | 25±4 | 23±4 | 24±5 | 25±6 | 23±4 | .863 |
| Cohort 1–5 (number) | 71/46/16/33/14 | 59/46/55/198/40 | 14/4/1/7/2 | 18/24/6/10/4 | 9/8/3/6/2 | 30/10/6/10/6 | .536 |
| Positive and Negative Syndrome Scale | |||||||
| Positive | 20±7 | — | 20±8 | 22±7 | 19±8 | 22±6 | .118 |
| Negative | 21±8 | — | 24±9 | 21±8 | 20±10 | 22±8 | .273 |
| General | 44±12 | — | 45±8 | 43±12 | 41±13 | 45±10 | .746 |
| Total | 85±23 | — | 89±20 | 85±25 | 80±29 | 89±20 | .897 |
| 295.1 | 4 | — | 1 | 2 | 1 | 0 | — |
| 295.3 | 86 | — | 11 | 32 | 16 | 27 | — |
| 295.4 | 13 | — | 4 | 4 | 1 | 4 | — |
| 295.7 | 2 | — | 1 | 1 | 0 | 0 | — |
| 295.9 | 5 | — | 2 | 0 | 1 | 2 | — |
| 297.1 | 1 | — | 1 | 0 | 0 | 0 | — |
| 298.8 | 1 | — | 0 | 1 | 0 | 0 | — |
| 295.x | 68 | — | 8 | 22 | 9 | 29 | — |
Note: Values are shown as mean ± SD. Schizophrenia (Schiz) subjects were divided into discovery and validation sets to determine the reproducibility of the molecular profiles observed in group 1 (main changes in immune factors) and group 2 (main changes in growth factors and hormones). Cohorts 1–5 are defined in “Methods” section and the number of individuals in each cohort are indicated.